Lupus Therapeutics Market Report 2026

Lupus Therapeutics Market Overview

• Lupus Therapeutics market size has reached to $2.98 billion in 2025 • Expected to grow to $4.34 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Rising Research And Development Activities Fuels Lupus Therapeutics Market • Market Trend: Advancements In Lupus Diagnostics With Predictive Artificial Intelligence Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Lupus Therapeutics Market?

Lupus therapeutics refer to treatments and medications specifically designed to manage and alleviate the symptoms of lupus, an autoimmune disease where the body's immune system attacks its own tissues, leading to inflammation and damage in various organs. These therapeutics aim to reduce inflammation, suppress the overactive immune response, and improve the quality of life for patients. The main disease types of lupus therapeutics are systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus erythematosus, neonatal lupus, and others. Systemic lupus erythematosus (SLE) refers to a chronic autoimmune disease that affects various organs and tissues in the body and is characterized by inflammation and damage to these organs. The treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), biologics, antimalarial drugs, corticosteroids, and others. Drugs are administered through oral, subcutaneous, intravenous, and other and are used by various end users, such as hospitals and clinics, diagnostic laboratories, and others.

What Is The Lupus Therapeutics Market Growth Forecast?

The lupus therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.34 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising investment in biologic drug development, increasing demand for steroid-sparing therapies, growth in autoimmune disease research funding, expanding access to specialty rheumatology clinics, increasing healthcare expenditure on chronic autoimmune diseases. Major trends in the forecast period include rising adoption of biologic and targeted therapies, increasing focus on long-term disease control, growing emphasis on personalized lupus management, expansion of combination therapy approaches, rising awareness of early lupus diagnosis and treatment.

Global Lupus Therapeutics Market Segmentation

1) By Disease Type: Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, Neonatal Lupus 2) By Treatment Type: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Biologics, Antimalarial Drugs, Corticosteroids, Other Treatment Types 3) By Route Of Administration: Oral, Subcutaneous, Intravenous, Other Routes Of Administration 4) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users Subsegments: 1) By Systemic Lupus Erythematosus (SLE): Mild SLE, Moderate SLE, Severe SLE 2) By Cutaneous Lupus Erythematosus: Acute Cutaneous Lupus, Subacute Cutaneous Lupus, Chronic Cutaneous Lupus (Including Discoid Lupus) 3) By Drug-Induced Lupus Erythematosus: Medications Known To Cause Drug-Induced Lupus, Hydralazine, Procainamide, Isoniazid 4) By Neonatal Lupus: Heart-Related Neonatal Lupus, Skin-Related Neonatal Lupus

What Is The Driver Of The Lupus Therapeutics Market?

The increasing research and development activities are expected to propel the growth of the lupus therapeutics market going forward. Research and development activities refer to systematic investigation and experimentation aimed at advancing knowledge, technology, or product development in various fields. The increasing research and development activities is often driven by the need for innovation, advancements in technology, addressing emerging challenges, improving healthcare outcomes, and fostering economic growth through scientific discoveries and technological breakthroughs. Research and development activities help advance lupus therapeutics by discovering new treatments, improving existing therapies, and understanding the underlying mechanisms of the disease. For instance, in March 2023, a report released by the Congressional Research Service, a U.S.-based federal legislative agency, noted that the President’s FY2024 budget proposal allocates approximately $209.7 billion to research and development (R&D), representing an increase of $8.9 billion (4.4%) over the FY2023 estimated level of $200.8 billion. When adjusted for inflation to FY2024 dollars, this proposal corresponds to a constant-dollar increase of 2.4% compared with the FY2023 actual level. Therefore, the increasing research and development activities are driving the growth of the lupus therapeutics industry.

Key Players In The Global Lupus Therapeutics Market

Major companies operating in the lupus therapeutics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Roche Holdings Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Ltd, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited

Global Lupus Therapeutics Market Trends and Insights

Major companies operating in the lupus therapeutics market are focused on developing advanced blood tests with predictive artificial intelligence to enhance diagnostic accuracy and treatment efficacy. Blood tests with predictive artificial intelligence refer to diagnostic tools that use AI algorithms to analyze biomarkers in blood samples, predicting disease outcomes or treatment responses with greater accuracy. For instance, in March 2024, AMPEL BioSolutions LLC, a US-based precision medicine company, launched the LuGENE blood test, which predicts lupus flares and drug targets from gene expression utilizing predictive artificial intelligence (AI). The test is designed to revolutionize the management of lupus, an autoimmune disease, by providing personalized treatment options for patients. It identifies real-time abnormalities in gene expression that lead to inflammation and immune system dysfunction, which are targetable by medication.

What Are Latest Mergers And Acquisitions In The Lupus Therapeutics Market?

In April 2024, Takeda Pharmaceutical Company Limited, a Japan-based biotechnology company, acquired Nimbus Therapeutics' TYK2 program from Nimbus Lakshmi Inc. for an undisclosed amount. The acquisition of TAK-279 enhances Takeda's competitive position in the immunology market and expands its portfolio of treatments for immune-mediated diseases. Nimbus Lakshmi Inc. is a US-based biotechnology company that develops drugs for psoriasis, lupus, and other diseases.

Regional Outlook

North America was the largest region in the lupus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Lupus Therapeutics Market?

The lupus therapeutics market consists of revenues earned by entities by providing services such as autoantibody testing, anti-phospholipid antibody testing, and rheumatoid factor testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The lupus therapeutics market also includes sales of calcineurin inhibitors, immunosuppressants, anticoagulants, and antimalarial drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lupus Therapeutics Market Report 2026?

The lupus therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lupus therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.